Genocea Biosciences high volatility trend continues
 | By Rifka Kats | Macroaxis Story |
57% of stocks are less volatile than Genocea, and 78% of all traded equity instruments are projected to make higher returns than the company over the 60 days investment horizon. As many conservative investors are still indifferent towards current market risk, it is prudent, from our point of view, to go over Genocea Biosciences' current volatility. We are going to analyze if the current expected returns justify Genocea Biosciences' volatility.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Vlad Skutelnik
This firm currently holds 25.54 M in liabilities with Debt to Equity (D/E) ratio of 1.96, which is about average as compared to similar companies. The company has a current ratio of 1.94, which is within standard range for the sector. Genocea Biosciences holds a performance score of 13 on a scale of zero to a hundred. The company retains a Market Volatility (i.e. Beta) of 0.2706, which attests to not very significant fluctuations relative to the market. Let's try to break down what Genocea's beta means in this case. As returns on the market increase, Genocea Biosciences returns are expected to increase less than the market. However, during the bear market, the loss on holding Genocea Biosciences will be expected to be smaller as well. Although it is vital to follow Genocea Biosciences current price history, it is good to be conservative about what you can do with the information regarding equity current price movements. Our philosophy towards determining future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Genocea Biosciences expected return of 1.26 will be sustainable into the future, we have found twenty-seven different technical indicators, which can help you to check if the expected returns are sustainable. Use Genocea Biosciences jensen alpha, maximum drawdown, semi variance, as well as the relationship between the sortino ratio and potential upside to analyze future returns on Genocea Biosciences. Volatility is a rate at which the price of Genocea Biosciences or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Genocea Biosciences may increase or decrease. In other words, similar to Genocea's beta indicator, it measures the risk of Genocea Biosciences and helps estimate the fluctuations that may happen in a short period of time. So if prices of Genocea Biosciences fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility. Please read more on our technical analysis page.
Watch out for price decline
Please consider monitoring Genocea Biosciences on a daily basis if you are holding a position in it. Genocea Biosciences is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Genocea Biosciences stock to be traded above the $1 level to remain listed. If Genocea Biosciences stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Genocea Biosciences's Liquidity
Genocea Biosciences financial leverage refers to using borrowed capital as a funding source to finance Genocea Biosciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Genocea Biosciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Genocea Biosciences' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Genocea Biosciences' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Genocea Biosciences's total debt and its cash.
Is Genocea Biosciences valued fairly by the market?
Genocea Biosciences reported the previous year's revenue of 596.25 K. Net Loss for the year was (36.24 M) with loss before overhead, payroll, taxes, and interest of (26.95 M).
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Genocea Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.